Ascletis Pharma (HKG:1672) completed enrollment in a phase IIa study in the US evaluating ASC30 for the treatment of obesity, a Tuesday Hong Kong bourse filing said.
All 125 participants of the study are obese or overweight with at least one weight-related comorbidity.